002365.SHE Qianjiang Yongan Pharmaceutical Co Ltd
- Market cap
- CNY 3.60B
- P/E
- 31.4x
- P/B
- 1.74x
- ROE
- 7.4%
- Dividend yield
- 0.83%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002365.SHE undervalued?
Graham number002365.SHE trades 55.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Qianjiang Yongan Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Qianjiang Yongan Pharmaceutical Co Ltd yet.
Qianjiang Yongan Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Qianjiang Yongan Pharmaceutical Co Ltd
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces nutrition and health foods, water reducers and other related products, as well as customized services for nutrition and health intervention products. The company engages in scientific research and technical services, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmaceutical Co., Ltd. was founded in …
Full company profileQianjiang Yongan Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Qianjiang Yongan Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 549M | 933M | 1.01B | 1.37B | 1.17B | 1.57B | 1.46B | 973M | 839M | 783M | 1.26B |
| Gross Profit | 141M | 338M | 350M | 318M | 353M | 354M | 471M | 251M | 166M | 132M | 369M |
| Operating Income | 62.6M | 152M | 212M | 118M | 134M | 132M | 152M | 5.65M | 72.9M | -2.72M | 207M |
| EBITDA | 153M | 227M | 292M | 230M | 245M | 249M | 277M | 142M | 184M | 128M | 188M |
| Net Income | 62.3M | 133M | 179M | 89.9M | 106M | 111M | 140M | -12.3M | 61.8M | 22.5M | 153M |
| EPS | 0.22 | 0.46 | 0.62 | 0.31 | 0.37 | 0.39 | 0.48 | -0.04 | 0.21 | 0.08 | 0.52 |
| Balance Sheet | |||||||||||
| Total Assets | 1.27B | 1.58B | 1.93B | 1.91B | 2.16B | 2.29B | 2.42B | 2.35B | 2.31B | 2.20B | 2.30B |
| Total Liabilities | 96.2M | 235M | 323M | 251M | 350M | 329M | 321M | 299M | 267M | 219M | 233M |
| Shareholders' Equity | 1.17B | 1.34B | 1.58B | 1.61B | 1.76B | 1.87B | 2.02B | 1.98B | 1.99B | 1.99B | 2.07B |
| Cash & Short-term Investments | 105M | 150M | 57.7M | 502M | 748M | 548M | 832M | 956M | 921M | 231M | 225M |
| Total Debt | 10.1M | 127M | 2.00M | 3.00M | 122M | 20.4M | 40.0M | 10.0M | 39.5M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 84.5M | 197M | 314M | 240M | 207M | 102M | 387M | 244M | 106M | 139M | - |
| Capital Expenditure | 40.1M | 289M | 269M | 134M | 104M | 63.0M | 149M | 121M | 118M | 62.3M | 213M |
| Free Cash Flow | 44.4M | -92.2M | 44.5M | 105M | 102M | 38.8M | 238M | 100M | -12.3M | 76.8M | -102M |
| Ratios | |||||||||||
| ROE | 5.3% | 9.9% | 11.3% | 5.6% | 6.0% | 6.0% | 7.0% | -0.6% | 3.1% | 1.1% | 7.4% |
| ROA | 4.9% | 8.4% | 9.3% | 4.7% | 4.9% | 4.9% | 5.8% | -0.5% | 2.7% | 1.0% | 6.6% |
| Net Profit Margin | 11.3% | 14.3% | 17.8% | 6.6% | 9.0% | 7.1% | 9.6% | -1.3% | 7.4% | 2.9% | 12.1% |
| Debt to Equity | 0.01x | 0.09x | 0.00x | 0.00x | 0.07x | 0.01x | 0.02x | 0.01x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Qianjiang Yongan Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.83%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 132.8%
- Ex-dividend date
- Jun 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 29.9M | 0.10 | 132.8% |
| 2024 | CNY 29.8M | 0.10 | 48.3% |
| 2023 | CNY 29.5M | 0.10 | - |
| 2022 | CNY 1.57M | 0.01 | 1.1% |
| 2021 | CNY 29.4M | 0.10 | 26.4% |
| 2020 | CNY 43.1M | 0.15 | 40.8% |
| 2019 | CNY 29.5M | 0.10 | 32.8% |
| 2018 | CNY 19.7M | 0.07 | 11.0% |
| 2017 | CNY 18.8M | 0.06 | 14.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on May 15, 2018.
Who owns Qianjiang Yongan Pharmaceutical Co Ltd
- Insiders 27.67%
- Institutions 0.85%
- Public & others 71.49%
- Shares outstanding 295M
- Free float 209M
Qianjiang Yongan Pharmaceutical Co Ltd company profile
- Company name
- Qianjiang Yongan Pharmaceutical Co Ltd
- Ticker
- 002365.SHE
- ISIN
- CNE100000LZ9
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Mar 5, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 912
- Fiscal year end
- December
- Address
- No. 2 Guangze Avenue, Qianjiang, China, 433132
- Phone
- 86 72 8620 2737
- Website
- chinataurine.com
About Qianjiang Yongan Pharmaceutical Co Ltd
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces nutrition and health foods, water reducers and other related products, as well as customized services for nutrition and health intervention products. The company engages in scientific research and technical services, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmaceutical Co., Ltd. was founded in 2001 and is based in Qianjiang, China.
Qianjiang Yongan Pharmaceutical Co Ltd management
10- Mr. Rengui HongMD & Director · born 1983
- Mr. Shengjie XiongCFO & Secretary · born 1968
- Mr. Shi Hao DongDeputy General Manager · born 1971
- Mr. Xu WuSenior Management · born 1978
- Mr. Xiquan FangDeputy General Manager · born 1964
- Mr. Zhihua WangDeputy General Manager · born 1970
- Mr. Shaobo LiSenior Management · born 1987
- Mr. Wei YeDeputy General Manager · born 1984
- Mr. Wei DongSenior Management · born 1990
- Ms. Yong Hong DengSenior Management · born 1981